ZYNE has been the topic of a number of other research reports. LADENBURG THALM/SH SH reaffirmed a buy rating and issued a $26.00 price objective on shares of Zynerba Pharmaceuticals in a report on Wednesday, September 18th. Zacks Investment Research downgraded Zynerba Pharmaceuticals from a hold rating to a sell rating in a research note on Saturday, November 9th. Jefferies Financial Group restated a hold rating and issued a $11.00 price target on shares of Zynerba Pharmaceuticals in a research note on Monday, September 16th. Finally, Needham & Company LLC began coverage on Zynerba Pharmaceuticals in a research report on Monday, October 21st. They issued a buy rating and a $18.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $19.71.
ZYNE traded down $0.02 during trading on Thursday, hitting $5.63. The stock had a trading volume of 374,813 shares, compared to its average volume of 1,433,092. The firm has a market capitalization of $131.07 million, a P/E ratio of -2.16 and a beta of 4.62. The company’s 50-day moving average price is $7.01 and its 200 day moving average price is $10.30. Zynerba Pharmaceuticals has a twelve month low of $2.75 and a twelve month high of $16.47.
Hedge funds have recently bought and sold shares of the company. NEXT Financial Group Inc boosted its stake in shares of Zynerba Pharmaceuticals by 1,190.0% during the 2nd quarter. NEXT Financial Group Inc now owns 1,935 shares of the company’s stock worth $26,000 after acquiring an additional 1,785 shares in the last quarter. Prestige Wealth Management Group LLC acquired a new position in Zynerba Pharmaceuticals during the second quarter worth $54,000. Wells Fargo & Company MN raised its holdings in Zynerba Pharmaceuticals by 110.1% during the second quarter. Wells Fargo & Company MN now owns 4,205 shares of the company’s stock worth $57,000 after purchasing an additional 2,204 shares during the last quarter. Tower Research Capital LLC TRC purchased a new stake in Zynerba Pharmaceuticals during the second quarter worth $72,000. Finally, Sterling Investment Advisors Ltd. purchased a new stake in Zynerba Pharmaceuticals during the second quarter worth $81,000. Institutional investors own 45.21% of the company’s stock.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.
Recommended Story: Systematic Risk
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.